Chemomab Therapeutics Ltd. (ADR)
General ticker "CMMB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $58.8M (TTM average)
Chemomab Therapeutics Ltd. (ADR) does not follow the US Stock Market performance with the rate: -16.4%.
Estimated limits based on current volatility of 3.3%: low 2.47$, high 2.64$
Factors to consider:
- Total employees count: 37 as of 2022
- Top business risk factors: Limited operating history, Strategic risks and growth management, Operational and conduct risks, Transition to commercialization, Anticipated future losses
- Current price 35.0% below estimated low
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.80$, 10.13$]
- 2025-12-31 to 2026-12-31 estimated range: [2.58$, 7.21$]
Short-term CMMB quotes
Long-term CMMB plot with estimates
Financial data
| YTD | 2024-12-31 |
|---|---|
| Operating Revenue | $0.00MM |
| Operating Expenses | $14.74MM |
| Operating Income | $-14.74MM |
| Non-Operating Income | $0.79MM |
| R&D Expense | $0.01MM |
| Income(Loss) | $-13.95MM |
| Profit(Loss)* | $-13.95MM |
| Stockholders Equity | $13.54MM |
| Assets | $16.96MM |
| Operating Cash Flow | $-15.39MM |
| Capital expenditure | $0.00MM |
| Investing Cash Flow | $2.30MM |
| Financing Cash Flow | $9.87MM |
| Earnings Per Share** | $-0.78 |
| Ordinary share to ADR | 0.05x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.